Favorable Long-Term Outcome in Male Breast Cancer.

Enver Ozkurt Mustafa Tukenmez Ravza Yılmaz Neslihan Cabioğlu Mahmut Muslumanoglu Ahmet Said Dinççağ Abdullah İğci Vahit Özmen

Published in: European journal of breast health (2018)

MBC presents different clinicopathological and prognostic factors when compared to FBC. Our survival rates are higher than the average presented in available literature. Because of the high rate of hormone receptor positivity, hormonal therapy is the mainstay for the treatment of estrogen receptor (ER)+ male breast cancer.

Keyphrases

estrogen receptor
prognostic factors
systematic review
polycystic ovary syndrome
mesenchymal stem cells
endoplasmic reticulum
skeletal muscle